Observational studyPLoS medicine2024
Antimicrobial resistance prevalence in bloodstream infection in 29 European countries by age and sex: An observational study.
Observational study in PLoS medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed, 3 syntheses or guidelines pooled it, 55 citations in OpenAlex.
- Impact of COVID-19 on the prevalence of multi-drug-resistant bacteria: a literature review and meta-analysis.Antonie van Leeuwenhoek · 2025Pooled it
- Phenotypic and genotypic landscape of antibiotic resistance through One Health approach in Sri Lanka: A systematic review.Tropical medicine & international health : TM & IH · 2025Pooled it
- Risk factors for antimicrobial-resistantFrontiers in veterinary science · 2024Pooled it
- Antimicrobial resistance analysis of Klebsiella pneumoniae bloodstream infections based on a random forest algorithm: a longitudinal study based on data from tertiary hospitals in China from 2012 to 2023.International health · 2026Article
- Pathogenic bacterial profile and antimicrobial susceptibility patterns in odontogenic facial cellulitis among Egyptian patients: A cross-sectional study.Scientific reports · 2026Article
- Changes in the microbial spectrum and antimicrobial resistance of bloodstream infections in intensive care units before and during the COVID-19 pandemic.BMC infectious diseases · 2026Article
- Population-Level Uncoupling of Antimicrobial Usage and Resistance in Community-OnsetPathogens (Basel, Switzerland) · 2026Article
- Antimicrobial resistance in Palestine: Emerging hotspots and trends from a 4-year hospital-based study.IJID regions · 2026Article
- Mind the governance gap: a one health scoping review of national AMR performance indicators.npj antimicrobials and resistance · 2026Article
- [Pharmacokinetic and metabolic considerations of antibiotic usage in children and the elderly].Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz · 2026Review
- Prevalence and antimicrobial resistance patterns in patients with blood stream infections: a four-year retrospective study at a tertiary healthcare center in Lebanon.BMC microbiology · 2026Article
- Epidemiologic and Clinical Divergence of MRSA USA100 and USA300 in the United States.Antibiotics (Basel, Switzerland) · 2026Article
- Cross-border differences in public knowledge, awareness, behaviours and beliefs related to antibiotics and antimicrobial resistance across the island of Ireland.BMC public health · 2026Article
- Risk factors for bloodstream infections and mortality in carbapenem-resistant versus susceptible Klebsiella pneumoniae: a six-year retrospective cohort study.BMC infectious diseases · 2026Article
- Prevalence and antimicrobial resistance ofFrontiers in microbiology · 2026Article
- Factors Associated With the Antimicrobial Resistance Profile of UropathogenicInterdisciplinary perspectives on infectious diseases · 2026Article
- Burden of antimicrobial resistance in the WHO Southeast Asia and Western Pacific Regions, 1990-2021: a cross-country systematic analysis with forecasts to 2050.Military Medical Research · 2026Article
- Two decades of bacteraemia in Norway: an ecological study of incidence and shifts in microbial epidemiology, 2005-2024.Scientific reports · 2025Article
- Rising Prevalence of Multidrug-ResistantAntibiotics (Basel, Switzerland) · 2025Article
- A five-year retrospective analysis of antimicrobial resistance patterns in clinical bacterial isolates from the Jazeera University Laboratory in Mogadishu, Somalia.BMC microbiology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundAntibiotic usage, contact with high transmission healthcare settings as well as changes in immune system function all vary by a patient's age and sex. Yet, most analyses of antimicrobial resistance (AMR) ignore demographic indicators and provide only country-level resistance prevalence values. This study aimed to address this knowledge gap by quantifying how resistance prevalence and incidence of bloodstream infection (BSI) varied by age and sex across bacteria and antibiotics in Europe. METHODS AND
findingsWe used patient-level data collected as part of routine surveillance between 2015 and 2019 on BSIs in 29 European countries from the European Antimicrobial Resistance Surveillance Network (EARS-Net). A total of 6,862,577 susceptibility results from isolates with age, sex, and spatial information from 944,520 individuals were used to characterise resistance prevalence patterns for 38 different bacterial species and antibiotic combinations, and 47% of these susceptibility results were from females, with a similar age distribution in both sexes (mean of 66 years old). A total of 349,448 isolates from 2019 with age and sex metadata were used to calculate incidence. We fit Bayesian multilevel regression models by country, laboratory code, sex, age, and year of sample to quantify resistant prevalence and provide estimates of country-, bacteria-, and drug-family effect variation. We explore our results in greater depths for 2 of the most clinically important bacteria-antibiotic combinations (aminopenicillin resistance in Escherichia coli and methicillin resistance in Staphylococcus aureus) and present a simplifying indicative index of the difference in predicted resistance between old (aged 100) and young (aged 1). At the European level, we find distinct patterns in resistance prevalence by age. Trends often vary more within an antibiotic family, such as fluroquinolones, than within a bacterial species, such as Pseudomonas aeruginosa. Clear resistance increases by age for methicillin-resistant Staphylococcus aureus (MRSA) contrast with a peak in resistance to several antibiotics at approximately 30 years of age for P. aeruginosa. For most bacterial species, there was a u-shaped pattern of infection incidence with age, which was higher in males. An important exception was E. coli, for which there was an elevated incidence in females between the ages of 15 and 40. At the country-level, subnational differences account for a large amount of resistance variation (approximately 38%), and there are a range of functional forms for the associations between age and resistance prevalence. For MRSA, age trends were mostly positive, with 72% (n = 21) of countries seeing an increased resistance between males aged 1 and 100 years and a greater change in resistance in males. This compares to age trends for aminopenicillin resistance in E. coli which were mostly negative (males: 93% (n = 27) of countries see decreased resistance between those aged 1 and 100 years) with a smaller change in resistance in females. A change in resistance prevalence between those aged 1 and 100 years ranged up to 0.51 (median, 95% quantile of model simulated prevalence using posterior parameter ranges 0.48, 0.55 in males) for MRSA in one country but varied between 0.16 (95% quantile 0.12, 0.21 in females) to -0.27 (95% quantile -0.4, -0.15 in males) across individual countries for aminopenicillin resistance in E. coli. Limitations include potential bias due to the nature of routine surveillance and dependency of results on model structure.
conclusionsIn this study, we found that the prevalence of resistance in BSIs in Europe varies substantially by bacteria and antibiotic over the age and sex of the patient shedding new light on gaps in our understanding of AMR epidemiology. Future work is needed to determine the drivers of these associations in order to more effectively target transmission and antibiotic stewardship interventions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.